PEF-Block & Ribs Fractures

Ketamine

Brief Summary

Rib fractures are frequent injuries found approximately in 10% severe trauma patient. Rib fractures were correlated in many studies with a higher morbidity and mortality. This impaired outcome is mainly due to pulmonary complications consequences including especially pulmonary contusions. Frequently, patients present difficulty deep breathing and coughing. These adverse effects can lead to the development of atelectasis, hypoxia, and respiratory failure with mechanic ventilation recourse. Effective pain management may prevent these complications and reduce the likelihood of developing chronic pain. A multi-modal analgesia regimen is widely employed combining regional and systemic analgesia. Epidural analgesia is considered by many authors to be the gold standard of pain relief although many side-effects are frequently describe including hypotension, urinary retention nausea and vomiting. Paravertebral nerve blockade is an adequate alternative that provide similar quality of analgesia with lower incidence of complication. However, the failure rate associates with PVB is about 13% and it may be associated with hypotension (4.6%), accidental vascular puncture (3.8%), accidental pleural puncture (1.1%) and rarely pneumothorax (0.5%). Recently, a description of the intercostal paraspinal nerve block. This technic was performed for patients undergoing thoracic surgery without complications.More recently, a description of a new approach to provide thoracic analgesia named the Posterior Paramedian subchoroidal (PoPS) block. The authors consider this technique provide an analgesia of the anterior and the posterior branch of adjacent thoracic nerves. The investigators propose to investigate the effect of Posterior exothoracic fascial block.

Intervention / Treatment

  • Intravenous morphine patient-controlled analgesia (PCA) (PROCEDURE)
    Group 1 control: * Morphine titration at 0.1 mg/kg * Establishment of PCA morphine: * concentration 1mg/ml * 1ml bolus * refractory period of 7 minutes * no maximum dose per day. Premedication of the patient with Ketamine 0.15 mg/kg and Propofol 0.5 mg /kg
  • Block of the posterior exo-thoracic fascia with Ropivacaine (PROCEDURE)
    Group 2 PEF block: * Establishment of PCA morphine: * concentration 1mg / ml * 1ml bolus * refractory period of 7 minutes * no maximum dose per day. * Realization of a block of the posterior exo-thoracic fascia (PEF block) at the median level of ribs fractures with ropivacaine 5mg / mL, 3 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of ropivacaine bolus 2mg / ml at 0.1ml/kg every 4 hours. Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.
  • Block of paravertebral space with Ropivacaine (PROCEDURE)
    Group 3 paravertebral block: * Establishment of PCA morphine: * concentration 1mg / ml * 1ml bolus * refractory period of 7 minutes * no maximum dose per day. * Realization of a paravertebral block (BPV) at the median level of ribs fractures ropivacaine 5mg / mL, (0.3ml / kg) 1.5 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of bolus of ropivacaine 2mg / ml at 0.1ml / kg every 4 hours. Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia. In the case of failure of initial management with significant pain despite the iterative boli, epidural analgesia is used in recourse.

Condition or Disease

  • Chest Trauma With Ribs Fractures

Phase

  • Not Applicable

    • Study Design

    Study type: INTERVENTIONAL
    Status: Completed
    Study results: No Results Available
    Age: 18 Years to 80 Years
    Enrollment: 90 (ACTUAL)
    Funded by: Other
    Allocation: Randomized
    Primary Purpose: Treatment

    Masking

    Clinical Trial Dates

    Start date: Jun 18, 2018 ACTUAL
    Primary Completion: Jun 15, 2022 ACTUAL
    Completion Date: Jun 15, 2022 ACTUAL
    Study First Posted: Jan 11, 2018 ACTUAL
    Results First Posted: Aug 31, 2020
    Last Updated: Oct 14, 2022

    Sponsors / Collaborators

    Lead Sponsor: University Hospital, Montpellier
    Lead sponsor is responsible party
    Responsible Party: N/A

    Location

    Montpellier, Occitanie, France

    Participant Groups

    • Pain management use intravenous morphine patient-controlled analgesia (PCA)

    • Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of the posterior exo-thoracic fascia with Ropivacaine

    • Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of paravertebral space with Ropivacaine

    Eligibility Criteria

    Sex: All
    Minimum Age: 18
    Maximum Age: 80
    Age Groups: Adult / Older Adult
    Healthy Volunteers: Yes

    Inclusion Criteria:

    * Major patients (18-80 years old)
    * Affiliated to the social security
    * Hospitalized following severe trauma associated with at least 2 unilateral ribs fractures
    * EVA greater than or equal to 3 when coughing or when mobilizing care.
    * Management of the patient in the first 24 hours post trauma.
    * Patient not intubated.
    * Collection of informed written consent, notification on the anesthesia sheet.

    Exclusion Criteria:

    * Minor patients,
    * Patients under guardianship
    * Pregnant or lactating women
    * Allergy known to local anesthetics,
    * Severe coagulopathy,
    * Infection of the puncture site
    * Neuromuscular pathology
    * Chronic pain patients (long-term treatment with non-inflammatory steroidal, opioid, neuroleptic, antidepressant, antiepileptic),
    * Intubated patient

    Primary Outcomes
    • Consumption of opoïd 24 hours
    Secondary Outcomes
    • cough pain intensity 1 hour, 6hours, 12hours, 24hours

    More Details

    NCT Number: NCT03396692
    Acronym: PEF
    Other IDs: UF 9860
    Study URL: https://clinicaltrials.gov/study/NCT03396692
    Last updated: Sep 29, 2023